BioTuesdays

Tag - Michael Okunewitch

MediWound Logo
Markets

Maxim starts MediWound at buy; PT $25

Maxim Group initiated coverage of MediWound (NASDAQ:MDWD) with a “buy” rating and $25 price target. The stock closed at $11 on Dec. 21. MediWound is a commercial-stage company developing a bromelain-based platform to...

December 22, 2022
BioRestorative Therapies Logo
Markets

Maxim starts BioRestorative Therapies at buy; PT $6

Maxim Group initiated coverage of BioRestorative Therapies (NASDAQ:BRTX) with a “buy” rating and $6 price target. The stock closed at $2.46 on Sept. 27. BioRestorative is a cell therapy company developing BRTX-100 for...

September 28, 2022
Longeveron
Markets

Maxim starts Longeveron at buy; PT $14

Maxim Group initiated coverage of Longeveron (NASDAQ:LGVN) with a “buy” rating and $14 price target. The stock closed at $6.52 on March 23. Longeveron is developing a medicinal signaling cell therapy, Lomecel-B, for...

March 24, 2022
HCW Biologics
Markets

Maxim starts HCW Biologics at buy; PT $4

Maxim Group initiated coverage of HCW Biologics (NASDAQ:HCWB) with a “buy” rating and price target of $4. The stock closed at $2.28 on March 23. HCW Biologics is addressing inflammaging; the chronic, sterile, low-grade...

March 24, 2022
SeqLL
Markets

Maxim starts SeqLL at buy; PT $3

Maxim Group initiated coverage of SeqLL (NASDAQ:SQL) with a “buy” rating and price target of $3. The stock closed at $1.60 on Feb. 8. SeqLL is developing true single molecule sequencing (tSMS), a type of short-read...

February 9, 2022
Kiora Logo
Markets

Maxim starts Kiora Pharma at buy; PT $2.50

Maxim Group initiated coverage of Kiora Pharmaceuticals (NASDAQ:KPRX) with a “buy” rating and price target of $2.50. The stock closed at 80 cents on Jan. 18. Kiora is developing ophthalmic medicines including, KIO-101...

January 19, 2022
Citius Logo
Markets

Maxim starts Citius Pharma at buy; PT $4

Maxim Group launched coverage of Citius Pharmaceuticals (NASDAQ:CTXR) with a “buy” rating and $4 price target. The stock closed at $1.62 on Nov. 29. Citius is a late-stage company with two “de-risked” Phase 3 assets:...

November 30, 2021